Annotation Detail
Information
- Associated Genes
- NTRK1
- Associated Variants
-
NTRK1 AMPLIFICATION
(
ENST00000524377.7 )
NTRK1 AMPLIFICATION ( ENST00000524377.7 ) - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including CNS disease. Responses were observed in non-small cell lung cancer, colorectal cancer, mammary analogue secretory carcinoma, melanoma, and renal cell carcinoma, as early as 4 weeks after starting treatment and lasting as long as >2 years. No objective responses (per RECIST v1.1; ref. 38) were observed in patients whose tumors did not harbor gene fusions involving NTRK1/2/3, ROS1, or ALK, with the exception of 1 patient with an ALKF1245V mutant neuroblastoma.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/2958
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3983
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1280
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Entrectinib
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 28183697
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Entrectinib | Resitance or Non-Reponse | true |